share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Prasad Raju

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities

CRISPR Therapeutics | 4：持股变动声明
SEC announcement ·  03/18 17:46
Moomoo AI 已提取核心信息
Raju Prasad, the Chief Financial Officer of CRISPR Therapeutics AG (CRSP), completed a sale of 3,524 shares of common stock on March 15, 2024. The transaction was executed at a price of $72.69 per share, resulting in a total market value of $256,159.56. This sale followed an acquisition of 10,000 shares on March 14, 2024, through the exercise of derivative securities. After these transactions, Prasad's direct holdings in the company amount to 6,476 shares of common stock.
Raju Prasad, the Chief Financial Officer of CRISPR Therapeutics AG (CRSP), completed a sale of 3,524 shares of common stock on March 15, 2024. The transaction was executed at a price of $72.69 per share, resulting in a total market value of $256,159.56. This sale followed an acquisition of 10,000 shares on March 14, 2024, through the exercise of derivative securities. After these transactions, Prasad's direct holdings in the company amount to 6,476 shares of common stock.
CRISPR Therapeutics AG（CRSP）首席财务官拉朱·普拉萨德于2024年3月15日完成了3524股普通股的出售。该交易以每股72.69美元的价格执行，总市值为256,159.56美元。此次出售是在2024年3月14日通过行使衍生证券收购了1万股股票之后进行的。在这些交易之后，普拉萨德在公司的直接持有量为6,476股普通股。
CRISPR Therapeutics AG（CRSP）首席财务官拉朱·普拉萨德于2024年3月15日完成了3524股普通股的出售。该交易以每股72.69美元的价格执行，总市值为256,159.56美元。此次出售是在2024年3月14日通过行使衍生证券收购了1万股股票之后进行的。在这些交易之后，普拉萨德在公司的直接持有量为6,476股普通股。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息